BioSpace News Archive

Today, the U.S. Food and Drug Administration is extending the enforcement discretion policy for certain human cell, tissue, and cellular and tissue-based products (HCT/Ps).

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced the formation of its Scientific Advisory Board (SAB).

The Feinstein Institutes for Medical Research has been awarded a $15 million grant to study brain dysfunction tied to lupus by the National Institutes of Health.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the company will deliver a presentation at the MoneyShow Accredited Investor Virtual Event that is being held July 22 – 24, 2020.

In continuing its implementation of a fully comprehensive and integrated kidney care model, Dialyze Direct, the largest staff-assisted home dialysis provider in nursing facilities, announced today their strategic partnership with NANI (Nephrology Associates of Northern Illinois and Indiana), which is focused on improving patient care for those receiving dialysis treatments.

Philadelphia College of Osteopathic Medicine announced it will receive a $5 million gift, the largest in the College’s 121-year history, from Howard A. Hassman, DO ’83.

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President of Research and Development, will present progress of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, at the 2nd International Society for Vaccines Virtual Congress.

Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the closing of a previously announced expansion of the collaboration and licensing agreement with Sanofi Pasteur to develop mRNA vaccines for all infectious disease pathogens, following notice of early termination of the

The study did not achieve statistical significance on the primary endpoint - Conference call and webcast to be held today at 4:30 p.m. Eastern Time SAN DIEGO--( BUSINESS WIRE )-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from its 298 patient Phase 3 CLARITY study which combined two identical, double-blind, placebo-controlled studies evaluating the efficacy, safety and tolerability of pimavanserin as an adjun

Kiniksa Pharmaceuticals, Ltd. announced that it is commencing a public offering of $100.0 million of Class A common shares.